Sangamo Shares Surge 13% as Biotech Prepares for OTC Transition and FDA Submission

Sangamo Therapeutics shares climb 13% despite moving from Nasdaq to OTCQB, as it advances gene therapy ST-920 for Fabry disease and faces analyst skepticism.

Sangamo Therapeutics saw its stock climb 13.26% to close at $0.14 in the latest session, even as the company braces for a significant shift in its market listing. The California-based biotech is set to move from the Nasdaq to the OTCQB Venture Market, with trading on the senior exchange expected to halt from tomorrow morning.

The delisting stems from the stock's prolonged slide below the $1 threshold, a requirement for continued Nasdaq listing. While Sangamo has formally requested a hearing to contest the decision, the transition to over-the-counter trading represents a major blow to the company's visibility among institutional investors.

Pipeline Progress Offers Counterweight

Despite the market turbulence, Sangamo's clinical development efforts are gathering momentum. The company is advancing a rolling Biologics License Application (BLA) with the US Food and Drug Administration for ST-920, its gene therapy candidate targeting Fabry disease, a rare inherited metabolic disorder. Completion of this submission in the coming months will be a pivotal regulatory milestone.

Another pipeline asset, ST-503, has secured Fast Track designation from the FDA for neuropathic pain. Sangamo plans to present fresh data from its neurology pipeline at a medical conference in mid-May, highlighting progress with its zinc finger protein technology for epigenetic regulation.

Financial Position and Analyst Skepticism

Sangamo recently bolstered its balance sheet through a stock offering that raised approximately $25 million. However, the company's financial health remains under scrutiny. Analysts are projecting first-quarter results due in May, with consensus estimates calling for earnings of $0.01 per share on revenue of around $34 million.

The stock has drawn bearish calls from Wall Street. Zacks Research recently slapped a "Strong Sell" rating on the shares, setting a price target of $3.32, while a separate analyst assessment pegged the average target at $3.75. Short interest has climbed roughly 14%, reflecting deepening pessimism among traders betting against the stock.

Looking Ahead

The next few weeks will be critical for Sangamo as it navigates the OTC transition while pushing forward with its regulatory filings. The upcoming quarterly report will provide investors with a clearer picture of the company's cash position and operating expenses following the market segment change. For now, the biotech's fate hinges on whether its clinical catalysts can outweigh the stigma of leaving a major exchange.